SBIR/STTR Research Award

Mucus and ALI Models of the Human Intestine

Award identifier 5fbfb4a4f44b864e4072313504edd78b29adbdd14f2439da9abdff7610afde71Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$835,939

Program and phase

SBIR · Phase II

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Altis Biosystems, Inc.
Proposal award date
2025-06-15
Contract end date
2027-05-31
UEI
YNJPFV6C18Z9
Solicitation number
PA23-230
Topic code
300

Research abstract

Project Summary The mucus layer is the first line of defense against infiltration of microorganisms, digestive enzymes and acids, digested food particles, microbial by-products, and food-associated toxins. This layer coats the interior surface of the GI tract, lubricates luminal contents and acts as a physical barrier to bacteria and other antigenic substances present in the lumen. The moist, nutrient-rich mucus layer adjacent to the epithelial barrier of the GI tract is also essential in the maintenance of intestinal homeostasis and contains a thriving biofilm including beneficial and pathogenic microbial populations. However, mucus has proven difficult to study, owing to it compositional and functional complexity and a substantial lack of either high-quality purified samples or cell- based culture systems containing mucus. This project will establish a gastrointestinal (GI) model for both harvesting physiologically relevant mucus and an epithelial culture system that possesses a native mucus layer. Building on Altis’ capabilities to generate models with greater physiological relevance using donor-derived cells, this program will establish key protocols and workflows to ensure a reliable and reproducible mucus layer to additionally replicate in vivo GI morphology and function. In Aim 1, we will commercially manufacture pure, native, sterile human GI mucus from cultures of human small and large intestine. In Aim 2, we will establish a novel commercial air-liquid interface model of human primary GI epithelia and demonstrate applications relevant to GI drug absorption and metabolism. Based on prior discussions with our pharmaceutical development customers, we view the commercial potential for this model as strong, especially given the unique capabilities of Altis’ current platform.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

13 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $11,282,656. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.